This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Weiqi Chen: Innovator in 11-Beta Hydroxysteroid Dehydrogenase Type I Inhibitors
Introduction
Weiqi Chen is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds that serve as inhibitors for 11-beta-hydroxysteroid dehydrogenase type I. His work is crucial for advancing therapeutic options for various diseases.
Latest Patents
Weiqi Chen holds a patent for "Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors." This patent describes innovative compounds that act as inhibitors for 11-beta-hydroxysteroid dehydrogenase type I. These inhibitors are essential for treating, preventing, or slowing the progression of diseases that require such therapy. The compounds are characterized by a specific formula, including stereoisomers or pharmaceutically acceptable salts, where R* is an isotopically labeled hydroxypropyl moiety.
Career Highlights
Weiqi Chen is currently employed at Bristol-Myers Squibb Company, where he continues to engage in groundbreaking research. His work at this leading pharmaceutical company allows him to collaborate with other experts in the field and contribute to the development of innovative therapies.
Collaborations
Weiqi Chen has worked alongside talented colleagues, including Brad D Maxwell and Bach D Tran. These collaborations enhance the research environment and foster the exchange of ideas, leading to more effective solutions in medicinal chemistry.
Conclusion
Weiqi Chen's contributions to the field of 11-beta hydroxysteroid dehydrogenase type I inhibitors exemplify the impact of innovative research in medicine. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes in various diseases.